746670-86-0

Upstream product

• 31139-02-3 (1S,2R)-2-(methoxycarbonyl)cyclohex-4-ene-1-carboxylic acid 
• 100-51-6 benzyl alcohol 
• 746670-85-9 C₉H₁₁NO₃ 
• 56124-48-2 monomethyl 1,2,3,6-tetrahydrophthalate 

Downstream Products

• 746670-87-1 (1R,6S)-6-(benzyloxycarbonylamino)cyclohex-3-enecarboxylic acid 
• 1329602-70-1 C₂₀H₂₀N₂O₃S 
• 1329602-73-4 C₂₇H₃₄N₂O₁₀ 
• 1453117-99-1 N-[(1R,2S,4R,5S)-2-(benzyloxycarbonylamino)-4,5-epoxycyclohexane]-2,3,4-tri-O-acetyl-α-L-fucopyranosylamine 
• 1453118-03-0 N-[(1R,2S,4R,5R)-2-(benzyloxycarbonylamino)-4-hydroxy-5-(2-chloroethoxy)cyclohexane]-2,3,4-tri-O-acetyl-α-L-fucopyranosylamine 

Relevant academic research and scientific papers

Synthesis and characterization of linker-armed fucose-based glycomimetics

Glycomimetic molecules can be used to antagonize the action of carbohydrate-binding proteins (lectins) involved in biological processes of high relevance for human and plant disease. In this paper we describe the derivatization with appropriate linkers of

Second generation of fucose-based DC-SIGN ligands: Affinity improvement and specificity versus Langerin

DC-SIGN and Langerin are two C-type lectins involved in the initial steps of HIV infections: the former acts as a viral attachment factor and facilitates viral invasion of the immune system, the latter has a protective effect. Potential antiviral compounds targeted against DC-SIGN were synthesized using a common fucosylamide anchor. Their DC-SIGN affinity was tested by SPR and found to be similar to that of the natural ligand Lewis-X (LeX). The compounds were also found to be selective for DC-SIGN and to interact only weakly with Langerin. These molecules are potentially useful therapeutic tools against sexually transmitted HIV infection.

Enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert- butoxycarbonylamino)-2-(hydroxymethyl)-cyclohexylcarbamate using an iodolactamization as the key step

(Chemical Equation Presented) An efficient enantioselective synthesis of benzyl (1S,2R,4R)-4-(tert-butoxycarbonylamino)-2-(hydroxymethyl) cyclohexylcarbamate 2, an essential intermediate for a series of potent CCR2 antagonists, is described. The key step

Cyclic derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.